** Shares of biotech firm Aligos Therapeutics ALGS.O rise 3.8% to $27 premarket

** ALGS says it is raising $105 million in a private placement financing

** Co is selling ~2.1 million shares of common stock along with warrants to purchase up to ~2 million additional shares at a combined purchase price of $26.0825/shr

** Combined purchase price is at a 0.2% premium to the stock's last close

** Co says the funding will be used to start a mid-stage trial for ALG-000184, a treatment for chronic hepatitis B virus infection

** Co says the funding will extend its cash runway into the H2 of 2026

** Co has 3.6 million outstanding shares, with market cap of $93.4 million - LSEG data

** Jefferies and Piper Sandler are acting as placement agents

** ALGS shares more than doubled in 2024

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))